Hyperekplexia 4 (HKPX4) Cell Models for Research

Hyperekplexia 4 (HKPX4) is a rare hereditary neurological disorder characterized by an exaggerated startle response, hypertonia, and apnea. The exact prevalence is unknown, but it is estimated to affect fewer than 1 in 40,000 individuals worldwide. The condition typically presents in infancy and can lead to life-threatening episodes if not managed properly. There is no cure, and treatment focuses on symptom management with clonazepam and other medications. The clinical impact is significant, with affected individuals experiencing social stigma, developmental delays, and increased risk of sudden infant death syndrome (SIDS).

HKPX4 is an ideal model for studying inhibitory neurotransmission, particularly the glycinergic system. The disorder is caused by mutations in the GLRB gene, which encodes the beta subunit of the glycine receptor. Research on HKPX4 can provide insights into receptor assembly, trafficking, and synaptic function. Public datasets, such as ClinVar and UniProt, provide mutation information, and there is a need for cellular models to study the functional consequences of these mutations. Gene-edited cell lines with specific GLRB mutations are valuable tools for drug screening and mechanistic studies.

The primary pathway affected in HKPX4 is the glycinergic inhibitory signaling pathway. Glycine is a major inhibitory neurotransmitter in the spinal cord and brainstem. The glycine receptor is a pentameric ligand-gated chloride channel composed of alpha and beta subunits. Mutations in GLRB can lead to:

• • Impaired receptor assembly or trafficking to the cell membrane.
• • Reduced chloride conductance, leading to neuronal hyperexcitability.
• • Disrupted synaptic clustering due to altered interactions with gephyrin.

These defects result in an exaggerated startle response and hypertonia.

Data from ClinVar and literature. The majority of HKPX4 cases are due to mutations in GLRB, with a smaller proportion in GLRA1.

The glycinergic signaling pathway is the main deregulated network. Key nodes include:

• • Glycine receptor (GlyR) subunits: GLRA1, GLRB
• • Gephyrin: scaffolding protein that anchors GlyRs at synapses
• • Glycine transporter (GlyT1, GlyT2): regulate synaptic glycine levels
• • Chloride channels: downstream effectors

Mutations in GLRB disrupt the receptor complex, leading to reduced inhibitory postsynaptic currents and neuronal hyperexcitability.

Organoids, such as cerebral organoids, can be generated from patient iPSCs to model neuronal development and function. They offer a more physiologically relevant context than 2D cell lines.

• • Glycine receptor knockout mice: Global or conditional knockout of Glrb in mice recapitulates the hyperekplexia phenotype, including startle responses and hypertonia.
• • Zebrafish models: Morpholino or CRISPR-induced knockdown of glrb can be used for high-throughput drug screening.
• • Induced models: Pharmacological blockade of glycine receptors with strychnine can induce transient hyperekplexia-like symptoms in rodents.

CRISPR-Cas9 technology enables the generation of isogenic cell lines with specific GLRB mutations. These models are essential for studying the functional consequences of patient-specific variants. For example:

• • GLRB knockout cell lines: Complete loss of GLRB function, useful for studying receptor function and compensatory mechanisms.
• • Knock-in cell lines with pathogenic mutations: Such as the common missense mutation p.Arg450Gln, allow for allele-specific studies.

These gene-edited models are commercially available from various sources, providing sequence-verified, quality-controlled cells that accelerate research. They are valuable for drug screening, functional assays, and mechanistic studies.

Gene-edited cell lines are used to validate the pathogenicity of GLRB variants. By introducing specific mutations into a wild-type background, researchers can assess the impact on receptor expression, localization, and function. For example, a knockout line can be used to confirm that loss of GLRB leads to reduced glycine-induced chloride currents, while a knock-in line with a known pathogenic mutation can demonstrate dominant-negative effects.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput screening of compounds that modulate glycine receptor function. For instance, screening for positive allosteric modulators that enhance chloride conductance in mutant receptors could identify potential therapeutics. Additionally, these models can be used to study resistance to existing treatments, such as clonazepam, and to identify alternative drugs.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, are lethal in cells with specific GLRB mutations but not in wild-type cells. This approach can uncover novel therapeutic targets and biomarkers for patient stratification.